Please assess the completion status of the following clinical trial:

Trial Title: Spironolactone Against Anthracycline-induced Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* LVEF \>50%~* first diagnosed breast cancer~* female sex~Exclusion Criteria:~* Prior breast cancer and/or prior anthracycline exposure history~* LVEF \<50%~* Use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers and beta blockers~* Creatinin value \>2 mg/dl~* Presence of chronic kidney failure~* Potassium value \>5.3 mg/dl~* Presence of adrenal gland diseases,~* Presence of severe liver failure~* Co-morbidities such as coronary heart disease, hypertension, atrial fibrillation, and valvular heart disease.~* Male patients were excluded for the homogenization of the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Spironolactone (Type: ACTIVE_COMPARATOR): patients who randomized to spironolactone administered arm
- Placebo (Type: PLACEBO_COMPARATOR): Patients who randomized to placebo administered arm

Based on this trial design, predict the completion outcome and termination type (if applicable).